Summary
The effect of spironolactone on the metabolism of intravenously administered3H-digitoxin (80 µCi) was investigated in eight patients. In three of them the labelled glycoside was given on a second occasion after spironolactone treatment had been discontinued for at least 65 days. Of total urinary radioactivity 79 % was unaltered drug and 12 % consisted of water soluble compounds. No digitoxigenin or digoxigenin and only trace amounts (<2 %) of digoxin and the bis- and monoglycosides of digoxigenin were found. After spironolactone total urinary radioactivity was unchanged but the fraction eliminated as unchanged digitoxin fell from 79 to 66 % and the water soluble compounds increased from 12 to 26 % (p<0.05). In addition spironolactone caused a 20 % reduction in the half-life of serum radioactivity (p<0.01) and a 16 % reduction in the volume of distribution (p<0.05). Induction of hepatic enzymes by spironolactone is proposed to explain the alteration in the metabolism of digitoxin in man. Both the altered metabolic pattern and the reduction in the volume of distribution appear to contribute to the reduction in half-life.
Similar content being viewed by others
References
Abshagen, U., Rennekamp, H., Kuhlmann, J.: Pharmacokinetics of 4‴-methyldigoxin after pretreatment with spironolactone in man. Naunyn Schmiedeberg's Arch. Pharmacol. Suppl.285, R 1 (1974)
Anton, A.H., Sayre, D.F.: A study of the factors effecting the aluminium oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. exp. Ther.138 360–375 (1962)
Ashley, J.J., Brown, B.T., Okita, G.T., Wright, S.E.: The metabolites of cardiac glycosides in human urine. J. biol. Chem.232 315–322 (1958)
Brown, P., Brüschweiler, F., Pettit, G.R., Reichstein, T.: Field ionization mass spectrometry. III: cardenolides. Org. Mass. Spectrum5 573–597 (1971)
Buck, S.H., Lage, G.L.: Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse. Arch. int. Pharmacodyn.189 192–197 (1971)
Castle, H.C., Lage, G.L.: Excretion of3H-digitoxin and its metabolites following spironolactone pretreatment in rats. Drug Metab. Dis.1 590–597 (1973)
Doherty, J.E., Perkins, W.H., Mitchell, G.K.: Tritiated digoxin studies in human subjects. Arch. int. Med.108 531–539 (1961)
Doherty, J.E., Hall, W.H., Murphy, M.L., Beard, O.W.: New information regarding digitalis metabolism. Chest59 433–437 (1971)
Douglas, J.G., Hollifield, J.W., Liddle, G.W.: Treatment of low-renin essential hypertension. J. Amer. med. Ass.227 518–527 (1974)
Falkner, F.C., Frölich, J.C., Watson, J.T.: Mass spectrometry of the trimethylsilyl derivatives of some cardiac aglycones and monoglycosides. Org. Mass. Spectrum7 141–153 (1973)
Hamrick, M.E., Zampaglione, N.G., Stripp, B., Gilette, J.R.: Investigation of the effect of methyltestosterone, cortisone and spironolactone on the hepatic microsomal mixed function oxydase system in male and female rats. Biochem. Pharmacol.22 293–310 (1973)
Jelliffe, R.W., Buell, J., Kalaba, R., Sridhar, R., Rockwell, R., Wagner, J.G.: An improved method of digitoxin therapy. Ann. int. Med.72 453–464 (1970)
Jelliffe, R.W.: Discussion of the paper: Some aspects of the distribution and disposition of digitoxin in man (Lukas, D.S.). Ann. N.Y. Acad. Sci.179 359–361 (1971)
Katzung, B.G., Meyers, F.H.: Biotransformation of digitoxin in the dog. J. Pharmacol. exp. Ther.154 575–580 (1966)
Kuschinsky, K.: Bestimmung der Eiweißbindung verschiedener Herzglykoside mittels Sephadex®-Gelfiltration. Naunyn Schmiedeberg's Arch. Pharmak. exp. Path.259 394–399 (1968)
Lage, G.L., Spratt, J.L.:3H-Digoxin metabolism by adult male rat tissuesin vitro. J. Pharmacol. exp. Ther.149 248–256 (1965)
Lahrtz, Hg., Reinold, H.M., Van Zwieten, P.A.: Serumkonzentration und Ausscheidung von3H-Digitoxin beim Menschen unter normalen und pathologischen Bedingungen. Klin. Wschr.47 695–700 (1969)
Lukas, D.S.: Some aspects of the distribution and disposition of digitoxin in man. Ann. N. Y. Acad. Sci.179 338–359 (1971)
Lukas, D.S., DeMartino, A.G.: Binding of digitoxin and some related cardenolides to human plasma proteins. J. clin. Invest.48 1041–1053 (1969)
Lukas, D.S., Peterson, R.E.: Double isotope dilution derivative assay of digitoxin in plasma, urine and stool of patients maintained on the drug. J. clin. Invest.45 782–795 (1966)
Okita, G.T., Kelsey, F.E., Talso, P.J., Smith, L.B., Geiling, E.M.K.: Studies on the renal excretion of radioactive digitoxin in human subjects with cardiac failure. Circulation7 161–168 (1953)
Repke, K.: Die Bis- und Mono-digitoxoside des Digitoxigenins und Digoxigenins: Metaboliten des Digitoxins. Naunyn Schmiedeberg's Arch. exp. Path. Pharm.237 155–170 (1959)
Repke, K.: Metabolism of cardiac glycosides. Proc. First. Internat. Pharmacol. Mtg., Stockholm 1961,3, 47–73 Oxford: Pergamon Press 1963
Sadee, W., Abshagen, U., Finn, C., Rietbrock, N.: Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn Schmiedeberg's Arch. Pharmacol.283 303–318 (1974)
Selye, H., Krajny, M., Savoie, L.: Digitoxin poisoning: prevention by spironolactone. Science164 842–843 (1969)
Solomon, H.M., Reich, S., Spirt, N., Abrams, W.B.: Interactions between digitoxin and other drugsin vitro andin vivo. Ann. N.Y. Acad. Sci.179 362–368 (1971)
Solymoss, B., Classen, H.G., Varga, S.: Increased hepatic microsomal activity induced by spironolactone and other steroids. Proc. Soc. exp. Biol. (N.Y.)132 940–942 (1969)
Solymoss, B., Toth, S., Varga, S., Selye, H.: Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication. Toxicol. appl. Pharmacol.18 586–592 (1971)
Stahl, E.: Thin-layer chromatography, p. 870, 2nd ed., Berlin, Heidelberg, New York: Springer-Verlag 1969
Steiness, E.: Renal tubular secretion of digoxin. Circulation50 103–107 (1974)
Storstein, L.: Studies on digitalis. I. Renal excretion of digitoxin and its cardioactive metabolites. Clin. Pharmacol. Ther.16 14–24 (1974)
Stripp, B., Hamrick, M.E., Zampaglione, N.G., Gilette, J.R.: The effect of spironolactone on drug metabolism by hepatic microsomes. J. Pharmacol. exp. Ther.176 766–771 (1971)
Taylor, S.A., Rawlins, M.D., Smith, S.E.: Spironolactone — a weak inducer in man. J. Pharm. Pharmacol.24 578–579 (1972)
Vöhringer, H.F., Rietbrock, N.: Metabolism and excretion of digitoxin in man. Clin. Pharmacol. Ther.16 796–806 (1974)
Watson, J.T., Pelster, T.R., Sweetman, B.J., Frölich, J.C., Oates, J.A.: A display oriented data system for multiple ion detection with gas chromatography-mass spectrometry in quantifying biomedically important compounds. Anal. Chem.45 2071–2078 (1973)
Wirth, K.E., Frölich, J.C.: Effect of spironolactone on excretion of3H-digoxin and its metabolites in rats. Europ. J. Pharmacol.29 43–51 (1974)
Author information
Authors and Affiliations
Additional information
Fellow of the Paul Martini-Stiftung, Frankfurt/Main, Germany
Rights and permissions
About this article
Cite this article
Wirth, K.E., Frölich, J.C., Hollifield, J.W. et al. Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9, 345–354 (1976). https://doi.org/10.1007/BF00606547
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606547